NIKKEI 225
27,476.87 +91.62 (+0.33%) HANG SENG
19,567.69 -347.99 (-1.75%) CRUDE OIL
72.88 +3.62 (+5.23%) GOLD FUTURES
1,958.20 -25.60 (-1.29%) DOW
32,432.08 +194.55 (+0.60%) Bitcoin GBP
21,958.48 -632.58 (-2.80%)
ABIVAX Société Anonyme (0RA9.L)
| Previous close | 6.69 |
| Open | 6.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 6.90 - 6.90 |
| 52-week range | 6.90 - 6.90 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 633,458 |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.47 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Abivax adjusts its 2023 Financial Communication Calendar
EQS-News: ABIVAX / Key word(s): MiscellaneousAbivax adjusts its 2023 Financial Communication Calendar 16.03.2023 / 18:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax adjusts its 2023 Financial Communication CalendarPARIS, France, March 16, 2023 – 06:30 p.m. (CET) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic
- EQS Group
Abivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution
EQS-News: ABIVAX / Key word(s): MiscellaneousAbivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution 13.03.2023 / 12:00 CET/CESTThe issuer is solely responsible for the content of this announcement.COMPANY STATEMENTAbivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institutionPARIS, France, March 13, 2023 – 12:00 p.m. (CET) – Abivax SA (the “Company”, Euronext Paris: FR0012333284 – ABVX), a Pha
- EQS Group
Abivax publishes a prospectus in the context of its capital increase
EQS-News: ABIVAX / Key word(s): MiscellaneousAbivax publishes a prospectus in the context of its capital increase 23.02.2023 / 20:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax publishes a prospectus in the context of its capital increasePARIS, FRANCE, February 23, 2023 – 8:00 p.m. (CET) – Abivax (Euronext Paris: FR0012333284 – ABVX) (the “Company”), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune
